Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(10):1708–13.

Article  PubMed  Google Scholar 

Clarkston K, Tsai Y, Jackson K, Rosen MJ, Denson LA, Minar P. Development of infliximab target concentrations during induction in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2019;69(1):68–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Courbette O, Aupiais C, Viala J, Hugot J, Roblin X, Candon S, et al. Trough levels of infliximab at week 6 are predictive of remission at week 14 in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr. 2020;70(3):310–7.

Article  PubMed  Google Scholar 

Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, et al. Infliximab dependency in children with Crohn’s disease. Aliment Pharmacol Ther. 2009;29(7):792–9.

Article  CAS  PubMed  Google Scholar 

Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis. 2008;15(6):816–22.

Article  Google Scholar 

de Ridder L, Rings EHHM, Damen GM, Kneepkens FCM, Schweizer JJ, Kokke FTM, et al. Infliximab dependency in pediatric Crohn’s disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2007;14(3):353–8.

Article  Google Scholar 

Crombé V, Salleron J, Savoye G, Dupas J, Vernier-Massouille G, Lerebours E, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn’s disease: a population-based study. Inflamm Bowel Dis. 2011;17(10):2144–52.

Article  PubMed  Google Scholar 

Kang B, Choi SY, Choi YO, Lee S, Baek S, Sohn I, et al. Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in paediatric Crohn’s disease. J Crohns Colitis. 2019;13(2):189–97.

Article  PubMed  Google Scholar 

Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(9):1655-68.e3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711–5.

Article  PubMed  Google Scholar 

Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, et al. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med. 2016;54(7):1211–9.

Article  CAS  PubMed  Google Scholar 

Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503–12.

Article  CAS  PubMed  Google Scholar 

Eser A, Primas C, Reinisch S, Vogelsang H, Novacek G, Mould DR, et al. Prediction of individual serum infliximab concentrations in inflammatory bowel disease by a Bayesian dashboard system. J Clin Pharmacol. 2018;58(6):790–802.

Article  CAS  PubMed  Google Scholar 

El Hassani M, Marsot A. External evaluation of population pharmacokinetic models for precision dosing: current state and knowledge gaps. Clin Pharmacokinet. 2023;62(4):533–40.

Article  PubMed  Google Scholar 

Bauman LE, Xiong Y, Mizuno T, Minar P, Fukuda T, Dong M, et al. Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(3):429–39.

Article  PubMed  Google Scholar 

Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247–59.

Article  PubMed  Google Scholar 

Xiong Y, Mizuno T, Colman R, Hyams J, Noe JD, Boyle B, et al. Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn’s disease. Clin Pharmacol Ther. 2021;109(6):1639–47.

Article  CAS  PubMed  Google Scholar 

Wojciechowski J, Upton RN, Mould DR, Wiese MD, Foster DJR. Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies. AAPS J. 2017;19(4):1136–47.

Article  CAS  PubMed  Google Scholar 

Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, et al. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs. 2016;8(7):1407–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946–64.

Article  CAS  PubMed  Google Scholar 

Dubinsky MC, Phan BL, Singh N, Rabizadeh S, Mould DR. Pharmacokinetic dashboard-recommended dosing is different than standard of care dosing in infliximab-treated pediatric IBD patients. AAPS J. 2017;19(1):215–22.

Article  CAS  PubMed  Google Scholar 

Buurman DJ, Maurer JM, Keizer RJ, Kosterink JGW, Dijkstra G. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther. 2015;42(5):529–39.

Article  CAS  PubMed  Google Scholar 

Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36.

Article  CAS  PubMed  Google Scholar 

Samuels A, Punt N, Reifenberg J, Mizuno T, Colman R, Menke F, et al. Predictive performance of different population pharmacokinetic models in a real-world cohort of Crohn’s disease patients. Gastroenterology. 2022;162(3 Suppl.):S99-100.

Article  Google Scholar 

Kantasiripitak W, Outtier A, Wicha SG, Kensert A, Wang Z, Sabino J, et al. Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT Pharmacometrics Syst Pharmacol. 2022;11(8):1045–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frymoyer A, Hoekman DR, Piester TL, de Meij TG, Hummel TZ, Benninga MA, et al. Application of population pharmacokinetic modeling for individualized infliximab dosing strategies in Crohn disease. J Pediatr Gastroenterol Nutr. 2017;65(6):639–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–53.

Article  PubMed  Google Scholar 

Burgess CJ, Reilly C, Steward-Harrison L, Balouch F, Lewindon PJ. Utility of proactive infliximab levels in paediatric Crohn’s disease. Arch Dis Child. 2019;104(3):251–5.

Article  PubMed  Google Scholar